Related Experiment Videos
Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass
G Franceschini1, M Cassinotti, G Vecchio
1Center E. Grossi Paoletti, University of Milano, Italy.
Insights
Pravastatin improved lipid levels in familial combined hyperlipidemia (FCHL) patients but did not alter small, dense LDL particles, suggesting maximal lipid reduction is key for managing coronary risk.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Familial combined hyperlipidemia (FCHL) is a common genetic disorder linked to early myocardial infarction.
- Elevated total cholesterol, LDL cholesterol, and small, dense LDL particles contribute to high coronary risk in FCHL.
- Understanding pravastatin's effect on lipid profiles and LDL structure in FCHL is crucial.
Purpose of the Study:
- To evaluate pravastatin's efficacy in correcting plasma lipid and lipoprotein levels.
- To assess pravastatin's impact on LDL particle size and composition in FCHL patients.
- To determine if pravastatin favorably alters LDL structure in the context of FCHL.
Main Methods:
- Twelve FCHL patients received pravastatin (40 mg/d) for 12 weeks.
- Plasma lipid, lipoprotein, and apolipoprotein B (apoB) levels were measured.
- LDL particle size and composition (cholesteryl ester-apoB ratio) were analyzed.
Main Results:
- Pravastatin significantly reduced total cholesterol (21%) and LDL cholesterol (32%).
- HDL cholesterol increased by 6%, driven by a 73% rise in HDL2 cholesterol.
- LDL particles became smaller and richer in apoB after treatment, but abnormal distribution persisted.
Conclusions:
- Pravastatin favorably modifies lipid and lipoprotein levels in FCHL.
- The drug did not significantly alter the abnormal small, dense LDL particle phenotype.
- Maximal lipid-lowering strategies are likely necessary to mitigate coronary risk in FCHL.
Abstract:
Familial combined hyperlipidemia (FCHL) is the most common genetic lipid disorder among young survivors of myocardial infarction. Elevations of plasma total and low-density lipoprotein (LDL) cholesterol and the prevalence of small, dense LDL particles are both involved in the high coronary risk of FCHL patients. We investigated the ability of pravastatin to favorably correct plasma lipid and lipoprotein levels and LDL structure in FCHL patients. Twelve patients with FCHL, documented by studies of first-degree relatives, received pravastatin (40 mg/d) for 12 weeks. Pravastatin significantly lowered plasma total and LDL cholesterol levels by 21% and 32%, respectively. Triglyceride levels did not change, and apolipoprotein B (apoB) concentrations decreased by 9% (P = NS). High-density lipoprotein (HDL) cholesterol increased by 6% because of a significant 73% rise of HDL2 cholesterol. LDL were smaller (diameter, 24.5 +/- 0.5 nm), less buoyant, and apoB-rich (cholesteryl ester-apoB ratio, 1.64 +/- 0.46) in the selected patients compared with patients with familial hypercholesterolemia or healthy control subjects. LDL became even smaller (23.8 +/- 0.6 nm) and richer in apoB (cholesteryl ester-apoB ratio, 1.27 +/- 0.52) after pravastatin treatment. Although pravastatin favorably altered plasma lipid and lipoprotein levels in FCHL patients, the abnormal LDL particle distribution and composition were not affected. Because of the apparent resistance of the small, dense LDL to drug-induced modifications, a maximal lipid-lowering effect is needed to reduce coronary risk in FCHL patients.